| 1.27 -0.035 (-2.68%) | 06-20 12:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 |
1-year : | 2.06 |
| Resists | First : | 1.57 |
Second : | 1.76 |
| Pivot price | 1.47 |
|||
| Supports | First : | 1.25 |
Second : | 1.03 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.5 |
| MA(100) : | 1.36 |
MA(250) : | 2.96 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 1.4 |
D(3) : | 10.2 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 6.8 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HOOK ] has closed below the lower bollinger band by 2.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ HOOK ] is to continue within current trading range. Bollinger Bands are 14.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.31 | 1.31 - 1.32 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.29 - 1.31 | 1.31 - 1.32 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Fri, 23 May 2025
Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey
Thu, 22 May 2025
Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha
Mon, 07 Apr 2025
Hookipa Pharma stock hits 52-week low at $0.81 amid sharp decline - Investing.com
Wed, 05 Mar 2025
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline - Investing.com
Fri, 28 Feb 2025
HOOKIPA Pharma Inc. SEC 10-K Report - TradingView
Thu, 27 Feb 2025
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 19.2 (%) |
| Held by Institutions | 34.2 (%) |
| Shares Short | 189 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | -5.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.71 |
| Profit Margin | 0 % |
| Operating Margin | -885.3 % |
| Return on Assets (ttm) | -45.3 % |
| Return on Equity (ttm) | -105.8 % |
| Qtrly Rev. Growth | -94.5 % |
| Gross Profit (p.s.) | -5.16 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | -7.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 1.3 |
| Price to Cash Flow | -0.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|